Contineum Therapeutics, a clinical-stage biopharmaceutical company, is set to conduct a $75.0 million public offering of its Class A common stock.
The underwriters may have the option to purchase up to an additional $11.25 million of shares.
The offering is subject to market conditions and other factors, with no assurance of completion or specific terms.
Public Offering
Contineum Therapeutics plans a $75.0 million public offering of Class A common stock.
Underwriters
Goldman Sachs, Leerink Partners, Stifel, RBC Capital Markets, and William Blair are acting as joint book-running managers.
Registration Statement
The registration statement for the offering was filed with the SEC on May 14, 2025, and declared effective on May 23, 2025.
- The proposed public offering indicates Contineum's intent to raise capital for its drug development programs.
- The involvement of reputable book-running managers adds credibility to the offering.
- Completion of the offering will depend on market conditions and regulatory approvals.
Contineum Therapeutics aims to expand its financial resources through the public offering, demonstrating confidence in its innovative therapies.